Investigational drugs in early phase development for biliary cholangitis.

Investigational drugs in early phase development for biliary cholangitis. Expert Opin Investig Drugs. 2020 Nov 30;: Authors: Gochanour EM, Kowdley KV Abstract Introduction: With a large percentage of patients having an incomplete response or intolerance to current FDA approved medications, new therapies for the treatment of primary biliary cholangitis are in great demand. Areas covered: In this review, we assess currently available drugs as well as promising new therapies for the treatment of primary biliary cholangitis. A literature search was performed with the following search terms: "PBC treatment", "PBC therapeutics", "PBC clinical trials" and included original articles, meta-analyses, and systematic reviews from Jan 1, 1981, to January 1, 2020. ClinicalTrials.gov was accessed for data from ongoing trials. Expert opinion: Targeted drug therapies offer an alternative for patients who are unable to meet their therapeutic goals with either of the two currently approved treatment options. Specifically, new drugs targeting bile acid regulation, immune-modulation and fibrogenic pathways are currently in development with multiple agents showing encouraging early results with the ultimate goal of developing therapies that will achieve high rates of biochemical remission, will be well tolerated and improve symptoms and quality of life in patients with primary biliary cholangitis. Based on a review of the current literature, PPAR agonists...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research